The comprehensive review by Furberg 1 of natural statins and stroke raises a number of issues. Stroke was a secondary end point in these studies in patients with cardiovascular disease (CVD). Primary end-point trials in stroke are awaited. Surrogate markers can be valuable guides to the introduction of better therapies before large-scale trials are completed. LDL may be the best surrogate marker of prognosis in CVD. In stroke, the primary role of LDL is less clear, but the subgroup analyses and the association of LDL reduction with mechanisms of plaque stabilization imply the need for effective therapy. The new target of LDL Ͻ100 mg/dL (Ͻ2.5 mmol/L) may be difficult to achieve with some natural statins. The extent to which comparative trials between statins are necessary to demonstrate a class effect is debatable, as they seem to share many ancillary actions. 2 The effects of statins on fibrinogen are controversial. Epidemiological evidence suggests fibrinogen is an independent risk factor, but it is unnecessary as an additional predictor in models of CVD risk. No clinical trials have demonstrated that a reduction in fibrinogen alone will reduce events or the converse. In contrast to the non-peer-reviewed communication cited with its claimed 50% increase in fibrinogen, 1 we have published observational data of 19% to 23% median increases in fibrinogen with atorvastatin in 89 patients with familial hyperlipidemias 3 and a subset of 21 patients at high risk of CVD. 4 We have extended these observations to 201 patients with familial hyperlipidemias and have found a median increase of 13% (range Ϫ25% to 63%) at 12 weeks with atorvastatin 10 to 80 mg. Previously, 98 of the same patients showed a 5% median decrease (range Ϫ28% to 28%) in fibrinogen when initially treated with simvastatin 20 to 40 mg. The effects of atorvastatin seen in our studies contrast with data from larger randomized, placebo-controlled trials in different but commoner patient groups. 5 Our observations need to be investigated in randomized, placebo-controlled trials in specified patient groups, and any drug specificity or time course needs to be determined. [3] [4] [5] The consequences of large reductions in LDL as opposed to small rises in fibrinogen are unknown. However, LDL seems to be a stronger predictor of risk than fibrinogen.
Response
Wierzbicki et al support the view that the statins differ in their nonlipid actions; atorvastatin, in contrast to simvastatin, raises fibrinogen. The authors call for randomized clinical trials to determine the clinical importance of this finding.
In a surprising development within a week of the publication of the editorial, 1 the Food and Drug Administration (FDA) took action against a claim that statins can be used interchangeably. Its Division of Drug Marketing, Advertising, and Communications issued a Warning Letter 2 to Novartis for a "false or misleading" TV advertisement suggesting that its product "Lescol is similar in effectiveness to other cholesterol lowering agents including Pravachol, Mevacor, and Zocor, and that the only difference between these agents is cost." The agency pointed out that it has not been demonstrated that Lescol reduces cardiovascular morbidity and mortality and that "because of dosing differences, Lescol may cost more than the other agents." This action by the FDA has raised an interesting question. How will the agency apply the criteria behind this Warning Letter to other statins and other drug classes for which the primary documentation for efficacy is change in a surrogate outcome (surrogate efficacy)?
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